Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTGFRN drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTGFRN ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PTGFRN Products |
| Gene Delivery | PTGFRN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PTGFRN Products |
| Benchmark Ab | Anti-PTGFRN (Biosimilar Sequence) Recombinant positive control. |
View PTGFRN Products |
| Validator | PTGFRN siRNA Set For knockdown verification. |
View PTGFRN Products |
| Related Target A | CD9 Tetraspanin partner for exosome complexing |
View CD9 Products |
| Related Target B | CD81 Tetraspanin partner for exosome complexing |
View CD81 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Exosome complex validation | Native glycosylation via HEK293 expression for proper folding |
| Lack of Controls | Clinical Benchmark Antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live PTGFRN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTGFRN therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCs and exosome-targeted therapies. As a highly expressed protein in various cancers and a key marker on extracellular vesicles, the next wave of R&D is targeting PTGFRN-mediated delivery and tumor microenvironment modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Early Stage Biotech | Solid Tumors | Internalization Assay (Need high-purity ECD-Fc) |
| Exosome Targeting | Academic/Biotech | Diagnostics / Therapeutics | Complex Validation (Need Native HEK293 Proteins) |
| Bispecific | Emerging Pipeline | Immunotherapy | Heterodimer Validation (Need Cross-reactive Abs) |